Immunocore Holdings PLC Sponsored ADR (IMCR) – What Are Analysts Thinking About This Stock?

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report) have received an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $52.86.

Several brokerages recently commented on IMCR. Morgan Stanley cut their price target on shares of Immunocore from $43.00 to $42.00 and set an “equal weight” rating on the stock in a report on Friday, November 13th. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Mizuho upped their price objective on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. BTIG Research reiterated a “buy” rating on shares of Immunocore in a research note on Monday. Finally, JPMorgan Chase & Co. initiated coverage on Immunocore in a research report on Friday, August 21st. They set an “overweight” rating and a $50.00 target price for the company.

Get Our Latest Stock Analysis on IMCR

Immunocore Stock Down 3.7%

IMCR stock opened at $27.81 on Wednesday. The stock has a market cap of $1.43 billion, a P/E ratio of -42.78 and a beta of 0.82. Immunocore has a twelve month low of $27.31 and a twelve month high of $40.71. The business’s 50-day moving average price is $30.77 and its 200-day moving average price is $31.58. The company has a quick ratio of 4.59, a current ratio of 4.62 and a debt-to-equity ratio of 0.94.

Immunocore (NASDAQ:IMCR – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. The company had revenue of $102.22 million for the quarter, compared to analysts’ expectations of $152.09 million. On average, equities research analysts forecast that Immunocore will post -0.20 EPS for the current year.

Institutional Investors Weigh In On Immunocore

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMCR. Marshall Wace LLP increased its holdings in Immunocore by 4.0% during the 3rd quarter. Marshall Wace LLP now owns 614,728 shares of the company’s stock worth $18,620,000 after purchasing an additional 23,787 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Immunocore by 30.9% in the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock worth $17,919,000 after buying an additional 140,308 shares during the period. Braidwell LP purchased a new stake in shares of Immunocore in the 2nd quarter worth $16,552,000. Renaissance Technologies LLC grew its position in shares of Immunocore by 16.4% during the 1st quarter. Renaissance Technologies LLC now owns 164,000 shares of the company’s stock worth $4,945,000 after buying an additional 23,100 shares in the last quarter. Finally, HighVista Strategies LLC grew its position in shares of Immunocore by 75.6% during the 3rd quarter. HighVista Strategies LLC now owns 75,840 shares of the company’s stock worth $2,297,000 after buying an additional 32,655 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

See Also

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.